Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics won’t enroll more patients in the Phase 3 trial of its Duchenne muscular dystrophy gene therapy Elevidys, a test that was meant to act as confirmatory evidence for an approval in older boys. ...